MEP20308A - THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS - Google Patents
THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERSInfo
- Publication number
- MEP20308A MEP20308A MEP-203/08A MEP20308A MEP20308A ME P20308 A MEP20308 A ME P20308A ME P20308 A MEP20308 A ME P20308A ME P20308 A MEP20308 A ME P20308A
- Authority
- ME
- Montenegro
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- fluorophenyl
- ethyl
- treatment
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14313598A | 1998-08-28 | 1998-08-28 | |
| PCT/US1999/017331 WO2000012090A1 (en) | 1998-08-28 | 1999-07-29 | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP20308A true MEP20308A (en) | 2010-06-10 |
Family
ID=22502745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-203/08A MEP20308A (en) | 1998-08-28 | 1999-07-29 | THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP1105132B1 (no) |
| JP (1) | JP2002523460A (no) |
| KR (3) | KR100735513B1 (no) |
| CN (1) | CN1127954C (no) |
| AT (1) | ATE249830T1 (no) |
| AU (1) | AU764604B2 (no) |
| BG (2) | BG65416B1 (no) |
| BR (1) | BR9913242A (no) |
| CA (2) | CA2629396A1 (no) |
| CZ (1) | CZ300781B6 (no) |
| DE (2) | DE69911436T2 (no) |
| DK (1) | DK1105132T3 (no) |
| EA (1) | EA003791B1 (no) |
| EE (1) | EE04951B1 (no) |
| ES (1) | ES2204146T3 (no) |
| HK (1) | HK1040907B (no) |
| HR (2) | HRP20010140A2 (no) |
| HU (1) | HUP0202145A3 (no) |
| ID (1) | ID29601A (no) |
| IL (2) | IL141603A0 (no) |
| ME (1) | MEP20308A (no) |
| MX (1) | MXPA01002026A (no) |
| NO (2) | NO20010984L (no) |
| NZ (1) | NZ510083A (no) |
| PL (1) | PL195022B1 (no) |
| PT (1) | PT1105132E (no) |
| SK (1) | SK284858B6 (no) |
| TR (1) | TR200100670T2 (no) |
| TW (1) | TWI233802B (no) |
| UA (1) | UA74773C2 (no) |
| WO (1) | WO2000012090A1 (no) |
| ZA (1) | ZA200101466B (no) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| ES2281666T3 (es) | 2002-07-19 | 2007-10-01 | Biovitrum Ab | Novedosos derivados de piperazinil-pirazinona para el tratamiento de los desordenes relacionados con el receptor 5-ht2a. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169096A (en) | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
| US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
| ATE102482T1 (de) * | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| DE69105501T2 (de) * | 1990-06-01 | 1995-04-13 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol. |
| JPH05134149A (ja) * | 1991-11-08 | 1993-05-28 | Nippondenso Co Ltd | 光半導体モジユール |
| US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
| EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
| US9702597B1 (en) | 2016-02-18 | 2017-07-11 | King Fahd University Of Petroleum And Minerals | System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage |
-
1999
- 1999-07-29 DE DE69911436T patent/DE69911436T2/de not_active Expired - Fee Related
- 1999-07-29 SK SK269-2001A patent/SK284858B6/sk not_active IP Right Cessation
- 1999-07-29 EP EP99936000A patent/EP1105132B1/en not_active Expired - Lifetime
- 1999-07-29 IL IL14160399A patent/IL141603A0/xx active IP Right Grant
- 1999-07-29 KR KR1020067008591A patent/KR100735513B1/ko not_active IP Right Cessation
- 1999-07-29 BR BR9913242-7A patent/BR9913242A/pt not_active Application Discontinuation
- 1999-07-29 KR KR1020017002503A patent/KR100682799B1/ko not_active IP Right Cessation
- 1999-07-29 HU HU0202145A patent/HUP0202145A3/hu unknown
- 1999-07-29 EE EEP200100122A patent/EE04951B1/xx not_active IP Right Cessation
- 1999-07-29 KR KR1020067003420A patent/KR100764532B1/ko not_active IP Right Cessation
- 1999-07-29 CN CN99810423A patent/CN1127954C/zh not_active Expired - Fee Related
- 1999-07-29 CA CA002629396A patent/CA2629396A1/en not_active Abandoned
- 1999-07-29 EA EA200100201A patent/EA003791B1/ru not_active IP Right Cessation
- 1999-07-29 EP EP03013686A patent/EP1362589B1/en not_active Expired - Lifetime
- 1999-07-29 CA CA002341891A patent/CA2341891C/en not_active Expired - Fee Related
- 1999-07-29 DK DK99936000T patent/DK1105132T3/da active
- 1999-07-29 JP JP2000567207A patent/JP2002523460A/ja active Pending
- 1999-07-29 PL PL99346342A patent/PL195022B1/pl not_active IP Right Cessation
- 1999-07-29 DE DE69941134T patent/DE69941134D1/de not_active Expired - Fee Related
- 1999-07-29 ID IDW20010489A patent/ID29601A/id unknown
- 1999-07-29 AU AU51359/99A patent/AU764604B2/en not_active Ceased
- 1999-07-29 NZ NZ510083A patent/NZ510083A/en active IP Right Revival
- 1999-07-29 MX MXPA01002026A patent/MXPA01002026A/es not_active IP Right Cessation
- 1999-07-29 TR TR2001/00670T patent/TR200100670T2/xx unknown
- 1999-07-29 WO PCT/US1999/017331 patent/WO2000012090A1/en active Application Filing
- 1999-07-29 UA UA2001032044A patent/UA74773C2/uk unknown
- 1999-07-29 ME MEP-203/08A patent/MEP20308A/xx unknown
- 1999-07-29 PT PT99936000T patent/PT1105132E/pt unknown
- 1999-07-29 CZ CZ20010726A patent/CZ300781B6/cs not_active IP Right Cessation
- 1999-07-29 AT AT99936000T patent/ATE249830T1/de not_active IP Right Cessation
- 1999-07-29 ES ES99936000T patent/ES2204146T3/es not_active Expired - Lifetime
- 1999-08-23 TW TW088114405A patent/TWI233802B/zh not_active IP Right Cessation
-
2001
- 2001-02-21 ZA ZA200101466A patent/ZA200101466B/en unknown
- 2001-02-22 IL IL141603A patent/IL141603A/en not_active IP Right Cessation
- 2001-02-23 BG BG105289A patent/BG65416B1/bg unknown
- 2001-02-23 BG BG101099A patent/BG109953A/bg unknown
- 2001-02-27 HR HR20010140A patent/HRP20010140A2/hr not_active Application Discontinuation
- 2001-02-27 NO NO20010984A patent/NO20010984L/no not_active Application Discontinuation
-
2002
- 2002-01-29 HK HK02100699.2A patent/HK1040907B/zh not_active IP Right Cessation
-
2008
- 2008-08-12 HR HR20080389A patent/HRP20080389A2/xx not_active Application Discontinuation
-
2009
- 2009-03-13 NO NO20091111A patent/NO20091111L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI925342A0 (fi) | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi | |
| PT840601E (pt) | Thip para o tratamento de desordens do sono | |
| SE9802208D0 (sv) | Novel compounds | |
| DE69800859D1 (de) | Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen | |
| SE9902267D0 (sv) | New compounds | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| SE9802209D0 (sv) | Novel compounds | |
| AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
| MY133169A (en) | Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect | |
| HRP20080389A2 (en) | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| DE60004833D1 (de) | Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung | |
| BR9708037A (pt) | Método para o tratamento de abuso de substância | |
| EA200200656A1 (ru) | НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ | |
| AP2000002002A0 (en) | Method of treatment. | |
| YU15301A (sh) | PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA | |
| YU40198A (sh) | Postupak za tretiranje zavisnosti od supstance |